Altre lingue HLB Therapeutics Co.,Ltd.

Azioni

A115450

KR7115450009

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
11.660 ^KRW	-2,51%		-3,95%	+165,91%

18/03	HLB Therapeutics Co.,Ltd. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	HLB Therapeutics Co.,Ltd. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd.	01/04
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.	07/07/23
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.	29/06/23
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors	21/06/23
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.	21/06/23
HLB Therapeutics Co.,Ltd. announced that it has received KRW 2.5 billion in funding	16/06/23
HLB Therapeutics Co.,Ltd. announced that it has received KRW 5 billion in funding	16/06/23
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259	14/04/23
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors	13/03/23
Oblato, Inc. announced that it has received KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.	14/02/23
Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.	06/02/23
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors	01/02/23
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd.	12/01/23
HLB Therapeutics to Raise 13 Billion Won via Stock Sale	04/01/23
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 13.0088 billion in funding from HLB Co., Ltd.	04/01/23
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HLB Therapeutics Co.,Ltd.

Azioni

A115450

KR7115450009

Altre lingue

Filtri